Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer
Articolo
Data di Pubblicazione:
2003
Citazione:
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer / E. Kubista, J. Glaspy, F.A. Holmes, M.D. Green, J. Hackett, T. Neumann, F. Marques, L. Meza, D. Miles, M. Moore, J. O'Shaughnessy, M.J. Piccart, G.E. Richardson, H. Samonigg, A. Santoro, M. Savin, M.R. Schaafsma, S. Siena, J. Shogan, S. Vukelja, I. Wiznitzer. - In: CLINICAL BREAST CANCER. - ISSN 1526-8209. - 3:6(2003 Feb), pp. 391-398. [10.3816/CBC.2003.n.003]
Abstract:
Bone pain is a common side effect of treatment with filgrastim. Pegfilgrastim is a pegylated long-acting analogue of filgrastim that is administered once per chemotherapy cycle. The profile of prospectively defined, patient-reported bone pain judged by the investigators as related to study drug was analyzed retrospectively for each drug using data from two comparable phase III trials. These multicenter, randomized, double-blind, noninferiority trials compared once-per-cycle pegfilgrastim (6 mg, study 1 or 100 μg/kg, study 2) to daily filgrastim 5 μg/kg in patients with stage II-IV breast cancer undergoing multiple cycles of myelosuppressive chemotherapy (doxorubicin/docetaxel). Subcutaneous once-per-cycle pegfilgrastim 6-mg and 100-μg/kg doses were administered to 76 and 150 patients, respectively; subcutaneous daily filgrastim 5 μg/kg was administered to a total of 227 patients. Because bone pain in study 1 was higher (P = 0.044) in every cycle compared with study 2, all analyses were performed separately for each study. No statistically significant differences in incidence, severity, or duration were observed between patients receiving either once-per-cycle pegfilgrastim or daily filgrastim in either study. Bone pain incidence and severity were significantly greater (P < 0.001) in cycle 1 of both studies compared with later cycles. Among patients with bone pain, a trend towards earlier onset with pegfilgrastim was observed but was not associated with increased bone pain severity or duration. In patients who received a fixed 6-mg dose of pegfilgrastim, the overall bone pain incidence was similar when analyzed by body weight (< 60 kg, 60-100 kg, > 100 kg). No patients were withdrawn from either study for bone pain
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Fixed-weight dosing; Neutrophil growth factor; Phase III clinical trial; Retrospective analysis
Elenco autori:
E. Kubista, J. Glaspy, F.A. Holmes, M.D. Green, J. Hackett, T. Neumann, F. Marques, L. Meza, D. Miles, M. Moore, J. O'Shaughnessy, M.J. Piccart, G.E. Richardson, H. Samonigg, A. Santoro, M. Savin, M.R. Schaafsma, S. Siena, J. Shogan, S. Vukelja, I. Wiznitzer
Link alla scheda completa: